Repligen Corporation Reports Preliminary Financial Results for the Quarter and Nine-Month Fiscal Period Ended December 31, 2011

WALTHAM, Mass.--(BUSINESS WIRE)--Repligen Corporation (NASDAQ:RGEN) today reported preliminary financial results for the quarter and nine-month fiscal period ended December 31, 2011. These results reflect significant accomplishments of the Company during the period, highlighted by the completion of our acquisition of Novozymes Biopharma Sweden AB on December 20, 2011 and the successful filing of the Company’s first new drug application (NDA) for SecreFlo™ on December 21, 2011. These preliminary results include estimates of the results of operations from December 21- December 31, 2011 for our new subsidiary Repligen Sweden AB (previously Novozymes Biopharma Sweden AB), but exclude any purchase accounting adjustments associated with the acquisition. The Company was able to acquire the net assets of Novozymes Biopharma Sweden AB at a purchase price significantly below the fair market value of the acquired net assets, thus the Company anticipates recording a gain on bargain purchase once purchase accounting is completed.